Crossmark

3478 Baseline characteristics in the tolebrutinib phase 3 primary progressive multiple sclerosis perseus clinical trial

Crossref DOI link: https://doi.org/10.1136/bmjno-2025-ANZAN.61

Published Online: 2025-10-23

Published Print: 2025-10

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Fox, Robert J

Reich, Daniel S

Traboulsee, Anthony

Oreja-Guevara, Celia

Giovannoni, Gavin

Vermersch, Patrick

Syed, Sana

Sun, Furong

Salloum, Naji

Turner, Timothy J

Wallstroem, Erik

Bar-Or, Amit

Parratt, John
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04458051 at ClinicalTrials.gov

Documents that mention this clinical trial

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
https://doi.org/10.1136/jitc-2021-003551

3478 Baseline characteristics in the tolebrutinib phase 3 primary progressive multiple sclerosis perseus clinical trial
https://doi.org/10.1136/bmjno-2025-anzan.61
License Information

License valid from 2025-10-22